论文部分内容阅读
采用随机分组的方法对149例晚期非小细胞肺癌以不同剂量顺铂联合环磷酰胺、阿霉素治疗。目的主要是观察其近期疗效和毒副反应。依顺铂的剂量及用法不同分为三组。中小剂量顺铂组为20mg／次×5天；中剂量顺铂组为40mg／次×3天；大剂量顺铂组为100mg／次。结果显示：小、中、大剂量顺铂组的疗效（CR＋PR）分别为36.54％（19／52）、38.18％（21／55）、40．48％（17／42）。三组间无显著差异（P＞0.05）。中剂量顺铂组肾毒性发生率最低。研究分析提示；以中剂量顺铂联合环磷酰胺、阿霉素治疗晚期非小细胞肺癌疗效较好，肾毒性低，经济方便，是值得推荐的治疗方案。
A randomized method was used to treat 149 patients with advanced non-small cell lung cancer with different doses of cisplatin combined with cyclophosphamide and doxorubicin. The purpose is mainly to observe its short-term efficacy and toxicity. According to the dose and usage of cisplatin, they are divided into three groups. The small and medium dose of cisplatin was 20 mg/time x 5 days; the middle dose of cisplatin was 40 mg/time x 3 days; the high dose of cisplatin was 100 mg/time. The results showed that the efficacy (CR+PR) of the small, medium, and high doses of cisplatin was 36.54% (19/52), 38.18% (21/55), and 40.48% (17/42), respectively. There was no significant difference between the three groups (P>0.05). The incidence of nephrotoxicity was lowest in the middle-dose cisplatin group. Research and analysis suggest that the use of middling cisplatin combined with cyclophosphamide and doxorubicin for the treatment of advanced non-small cell lung cancer has good curative effect, low nephrotoxicity, and economic convenience. It is a recommended treatment plan.